Related Experiment Videos
Topical metronidazole does not abate UVB-induced erythema
M Guarrera1, C Brusati, A Rebora
1Department of Endocrinological and Metabolic Diseases, Section of Dermatology, University of Genoa, Italy. rebdermo@unige.it
Dermatology (Basel, Switzerland)
|October 5, 2001
Summary
Topical metronidazole 1% cream did not significantly reduce UVB-induced erythema in healthy subjects. This suggests that metronidazole
Area of Science:
- Dermatology
- Pharmacology
Background:
- Topical metronidazole is commonly used for rosacea, with its efficacy often attributed to anti-inflammatory properties.
- Erythema severity is a key indicator in rosacea management.
Purpose of the Study:
- To investigate the efficacy of metronidazole 1% cream in reducing ultraviolet B (UVB)-induced erythema in healthy subjects.
- To evaluate whether the anti-inflammatory activity of metronidazole contributes to its effect on erythema.
Main Methods:
- Nine healthy subjects received UVB irradiation on their forearms.
- Treated areas included metronidazole 1% cream, vehicle control, and an untreated control.
- Erythema intensity was objectively measured using a Chromameter over 96 hours post-irradiation.
Main Results:
- Redness (erythema) naturally diminished over the 96-hour observation period.
- Neither metronidazole 1% cream nor the vehicle significantly altered the UVB-induced erythema compared to the untreated control.
Conclusions:
- Metronidazole 1% cream, in the tested vehicle, did not effectively reduce UVB-induced erythema in this study.
- The findings challenge the sole attribution of topical metronidazole's efficacy in rosacea to anti-inflammatory actions.
- Further research is needed to explore alternative mechanisms of action for topical metronidazole in rosacea treatment.